Octapharma AG Announces First-Ever Research Grants Program, Demonstrating Commitment to Cutting-Edge Clinical Research

Special Octapharma 25th Anniversary Program Will Support U.S. Research on
Immunology, Coagulation Disorders and Critical Care

LACHEN, Switzerland & HOBOKEN, N.J.--(Business Wire)--
Octapharma AG, one of the world`s largest plasma products manufacturers, is
celebrating its 25th anniversary by demonstrating its commitment to cutting-edge
clinical research with the launch of the Octapharma 25th Anniversary Grants
Program. The company`s first ever grants program is only available to
researchers based in the United States and will be administered exclusively by
Octapharma USA, the Swiss company`s rapidly-growing U.S. subsidiary.

"In recognition of Octapharma`s milestone 25th anniversary, we wanted to support
research initiatives impacting the healthcare issues that are central to our
mission while at the same time emphasizing how important the U.S. market is to
our company," said Octapharma Chairman Wolfgang Marguerre. "We have been
committed to patient care and medical innovation since day one and our vision of
providing patients with the safest, highest quality plasma products available is
stronger than ever. Our goal continues to be to help people around the world
live better lives and no market is more important to Octapharma than the U.S."

The Octapharma 25th Anniversary Grants Program will support clinical or
pre-clinical research focusing on human protein therapies in coagulation
disorders, immunology, intensive care and emergency medicine. Grant applications
will be accepted online only at www.octapharmagrants.com. All grant requests
will be evaluated by the Octapharma 25th Anniversary Grants Committee. Please
visit www.octapharmagrants.com for a complete description of the grants program,
including the application and review process.

"Octapharma is committed to supporting clinical and pre-clinical research
projects that promote excellence in patient care and provide valuable
information to the medical and patient community that may translate to better
management of disease and improvement in patient safety," said Octapharma USA
President Flemming Nielsen. "We have seen that there are tremendous unmet
medical needs throughout the U.S. and we hope the grants program will advance
Octapharma`s primary objective - helping patients enjoy the best possible
quality of life."

Octapharma AG

Octapharma AG is one of the world`s largest plasma products manufacturers and
has been committed to patient care and medical innovation for over 25 years.
Octapharma`s core business is the development, production and sale of high
quality human protein therapies, including immune globulin intravenous (IGIV).
In the U.S., Octapharma`s IGIV product, octagam (immune globulin intravenous
[human] 5%), is used to treat disorders of the immune system, and Octapharma`s
Albumin (Human) is indicated for the restoration and maintenance of circulating
blood volume. Based in Lachen, Switzerland, Octapharma employs over 2,500 people
and has biopharmaceutical experience in 70 countries worldwide, including the
United States, where Octapharma USA is headquartered in Hoboken, N.J. Octapharma
is the only plasma products manufacturer with two state-of-the-art production
sites licensed by the U.S. Food and Drug Administration, allowing the company to
ensure unparalleled production flexibility and sustainable supply. For more
information, please visit www.octapharma.com or call Octapharma USA at
201-604-1130.

Yankee Public Relations
Fred Feiner, 908-894-3930
fred@yankeepr.com

Copyright Business Wire 2009